News

Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and…

2 years ago

OrthoPediatrics Corp. Completes Acquisition of Pega Medical

WARSAW, Ind., July 05, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively…

2 years ago

Top International Academic Institutions Complete Independent Studies Validating C-POLAR™ Technology

Independent data verification at Hong Kong Metropolitan University, the Czech Academy of Sciences, Finland’s Tampere University, Massachusetts General Hospital, Harvard…

2 years ago

Inspire Medical Systems, Inc. to Report Second Quarter 2022 Financial Results on August 2, 2022

MINNEAPOLIS, July 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the…

2 years ago

Alignment Healthcare Welcomes Randall Fitzpatrick, Formerly of Optum, as Senior Vice President of Product

ORANGE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that…

2 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

      Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker…

2 years ago

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…

2 years ago

Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors

- Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed:…

2 years ago

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures…

2 years ago

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development…

2 years ago